Novo Nordisk A/S (NYSE:NVO) Shares Sold by Motley Fool Wealth Management LLC

Key Points

• Motley Fool Wealth Management LLC reduced its stake in Novo Nordisk A/S by 12.0% during the 1st quarter, now holding 89,838 shares valued at $6.24 million.
• Novo Nordisk A/S reported earnings of $0.97 per share, surpassing analysts' expectations of $0.93, with revenues totaling $11.69 billion for the quarter.
• The company has announced a semi-annual dividend of $0.4119 per share, providing a dividend yield of 240.0% with an ex-dividend date of August 18.

Motley Fool Wealth Management LLC decreased its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,838 shares of the company's stock after selling 12,297 shares during the period. Motley Fool Wealth Management LLC's holdings in Novo Nordisk A/S were worth $6,238,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NVO. SouthState Corp boosted its stake in Novo Nordisk A/S by 1.5% during the 1st quarter. SouthState Corp now owns 49,986 shares of the company's stock worth $3,471,000 after purchasing an additional 735 shares during the period. Nuveen LLC acquired a new stake in Novo Nordisk A/S during the 1st quarter worth $370,272,000. Aigen Investment Management LP boosted its stake in Novo Nordisk A/S by 302.6% during the 1st quarter. Aigen Investment Management LP now owns 34,284 shares of the company's stock worth $2,381,000 after purchasing an additional 25,769 shares during the period. Cooper Financial Group boosted its stake in Novo Nordisk A/S by 2.7% during the 1st quarter. Cooper Financial Group now owns 11,367 shares of the company's stock worth $789,000 after purchasing an additional 295 shares during the period. Finally, King Luther Capital Management Corp boosted its stake in Novo Nordisk A/S by 6.3% during the 1st quarter. King Luther Capital Management Corp now owns 17,944 shares of the company's stock worth $1,246,000 after purchasing an additional 1,063 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 4.7%

Shares of Novo Nordisk A/S stock opened at $51.06 on Monday. The firm has a fifty day moving average of $67.14 and a two-hundred day moving average of $71.47. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The company has a market cap of $227.98 billion, a P/E ratio of 14.03, a PEG ratio of 1.75 and a beta of 0.63. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be issued a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 45.05%.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target for the company. in a research note on Thursday, July 31st. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $93.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.